安罗替尼联合GP化疗方案治疗晚期非小细胞肺癌的疗效观察及血清肿瘤标志物水平的影响

Efficacy of arotinib combined with GP chemotherapy in the treatment of advanced non-small cell lung cancer and the influence of serum tumor markers

目的:探讨安罗替尼联合GP化疗方案治疗晚期非小细胞肺癌(NSCLC)的疗效及对血清肿瘤标志物水平的影响。方法:选取收治的72例NSCLC患者,随机分为观察组、对照组,各36例。对照组给予GP化疗方案治疗,观察组在此基础上联合安罗替尼治疗,对两组患者的临床疗效、血清肿瘤标记物、不良反应发生率、随访指标等进行统计对比。结果:治疗后观察组患者的客观缓解率(ORR)、疾病控制率(DCR)分别为58.33%(21/36)、72.22%(26/36),高于对照组患者分别为33.33%(12/36)、47.22%(17/36),差异有统计学意义(P<0.05)。治疗后观察组患者的角蛋白19片段抗原21-1(CYFRA21-1)、糖分解烯醇酶(NSE)、人非小细胞肺癌抗原(LTA)水平均低于对照组,差异有统计学意义(P<0.05)。治疗后观察组无进展生存期(PFS)、总体生存期(OS)水平均高于对照组,差异有统计学意义(P<0.05)。观察组、对照组不良反应发生率分别为25.00%(9/36)、13.89%(5/36),差异无统计学意义(P>0.05)。结论:安罗替尼联合GP化疗方案治疗晚期NSCLC的近期疗效显著,降低肿瘤标志物水平,延长患者的生存周期,且治疗期间安全性良好,值得临床推荐。

Objective To study the efficacy of arotinib combined with GP chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC)and the influence of serum tumor markers.Method 72 patients with NSCLC in our hospital were selected and randomly divided into observation group and control group,36 cases in each group.The control group was treated with GP chemotherapy,and the observation group was treated with arotinib on this basis.The clinical efficacy,serum tumor markers,incidence of adverse reactions and follow-up indicators of the two groups were statistically compared.Results After treatment,the objective remission rate(ORR)and disease control rate(DCR)of the observation group were 58.33%(21/36)and 72.22%(26/36),which were higher than those of the control group 33.33%(12/36)and 47.22%(17/36),respectively(P<0.05).After treatment,the levels of cytokeratin 19 fragment antigen 21-1(CYFRA21-1),glycolysis enolase(NSE)and human non-small cell lung cancer antigen(LTA)in the observation group were lower than those in the control group(P<0.05).After treatment,the PFS and OS of the observation group were higher than those of the control group(P<0.05).The incidence of adverse reactions in the observation group and the control group were 25.00%(9/36)and 13.89%(5/36),respectively.There was no significant difference between the two groups(P>0.05).Conclusion The short-term efficacy of arotinib combined with GP regimen in the treatment of advanced NSCLC is significant,which can reduce the level of tumor markers,prolong the life cycle of patients,and has good safety during the treatment,which is worthy of clinical recommendation.